Sygnature Discovery has incorporated an Azenta compound management storage system into its capabilities, enabling the storage of customer libraries as well. High-fidelity hit finding is a crucial initial step in successful drug discovery projects, especially as new drug targets become more challenging to pursue. The seamless integration of High Throughput Screening (HTS) and compound management is vital for identifying hits with precision and confidence.
Sygnature is also focused on enhancing the integrity of the entire compound-to-screening data process and aims to improve hit finding success for less druggable targets. This will be achieved through a tailored integration of hit finding technologies, including multimodal HTS diversity screens, fragment-based biophysics screening, and recently acquired affinity-selection mass spectrometry.
The state-of-the-art Azenta compound management system, combined with increased HTS screening capacity, allows for the automated management and screening of compounds from various sources in one centralized location. Sygnature now has the capability to store over 2 million compounds under optimal conditions for stability, with compound samples tracked automatically using Titian Mosaic from storage to the final HTS assay data point. This comprehensive end-to-end solution meets the current and future requirements for high-quality HTS hit finding.
This substantial investment aligns with the company's long-term vision of leading the drug discovery market in hit finding capabilities.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!